跳至主要内容
临床试验/JPRN-UMIN000011427
JPRN-UMIN000011427已完成1 期

A phase 1 / 2 trial of AMG0001 in patients with primary lymphedema - A phase 1 / 2 trial of AMG0001 in patients with primary lymphedema

AnGes MG, Inc.0 个研究点目标入组 20 人开始时间: 2013年8月8日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 65years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Fibrosis has supervened and become irreversible (ISL late stage II or worse). (2) Morphologically classified into hyperplasia (3) Lymphedema as a congenital associated malformation (e.g. Klippel-Trenaunay-Weber syndrome, Noonan syndrome, Turner's syndrome). (4) History, diagnosis or suspicion of malignant neoplasm. (5) History of invasive treatment for lymphedema (e.g. surgical reduction, liposuction, lymphaticovenous Anastomosis within 5 years), or history of surgery under general/spinal anesthesia in the affected limb.

研究者

发起方
AnGes MG, Inc.

相似试验

A phase 1 / 2 trial of AMG0001 in patients with... | 临床试验